RESUMEN
Hemophilus aphrophilus is an uncommon pathogen in man. It has rarely been reported as a cause of meningitis, exclusively in boys three years or younger. Osteomyelitis due to this organism is also rare. H. aphrophilus was responsible for meningitis, probable thoracic empyema, and ultimately vertebral osteomyelitis and suppurative psoas abscess formation in a woman following metrizamide myelography. The patient responded well to antibiotic treatment and surgical drainage. The organism was sensitive not only to chloramphenicol but also to newer cephalosporin antibiotics.
Asunto(s)
Absceso/complicaciones , Meningitis por Haemophilus/complicaciones , Osteomielitis/complicaciones , Absceso/tratamiento farmacológico , Anciano , Ampicilina/uso terapéutico , Cefamandol/uso terapéutico , Preescolar , Cloranfenicol/uso terapéutico , Femenino , Humanos , Lactante , Vértebras Lumbares/diagnóstico por imagen , Masculino , Meningitis por Haemophilus/tratamiento farmacológico , Meningitis por Haemophilus/fisiopatología , Osteomielitis/diagnóstico por imagen , Osteomielitis/terapia , Tomografía Computarizada por Rayos XRESUMEN
PURPOSE: To compare the efficacy and safety of inpatient oral antibiotic treatment (oral) versus standard parenteral antibiotic treatment (intravenous) for right-sided staphylococcal endocarditis in injection drug users. PATIENTS AND METHODS: In a prospective, randomized, non-blinded trial, febrile injection drug users were assigned to begin oral or intravenous (IV) treatment on admission, before blood culture results were available. Oral therapy consisted of ciprofloxacin and rifampin. Parenteral therapy was oxacillin or vancomycin, plus gentamicin for the first 5 days. Antibiotic dosing was adjusted for renal dysfunction. Administration of other antibacterial drugs was not permitted during the treatment or follow-up periods. Bacteremic subjects having right-sided staphylococcal endocarditis received 28 days of inpatient therapy with the assigned antibiotics. Test-of-cure blood cultures were obtained during inpatient observation 6 and 7 days after the completion of antibiotic therapy, and again at outpatient follow-up 1 month later. Criteria for treatment failure and for drug toxicity were prospectively defined. RESULTS: Of 573 injection drug users who were hospitalized because of a febrile illness and suspected right-sided staphylococcal endocarditis, 93 subjects (16.2%) had two or more sets of blood cultures positive for staphylococci; 85 of these bacteremic subjects (14.8%) satisfied diagnostic criteria for at least possible right-sided staphylococcal endocarditis (no other source of bacteremia was apparent) and entered the trial. Forty-four (oral, 19; IV, 25) of these 85 subjects completed inpatient treatment and evaluation including test-of-cure blood cultures. There were four treatment failures (oral, 1 [5.2%]; IV, 3 [12.0%]; not significant, Fisher's exact test). Drug toxicity was significantly more common in the parenterally treated group (oral, 3%; IV, 62%; P < 0.0001), consisting largely of oxacillin-associated increases in liver enzymes. CONCLUSIONS: For selected patients with right-sided staphylococcal endocarditis, oral ciprofloxacin plus rifampin is effective and is associated with less drug toxicity than is intravenous therapy.
Asunto(s)
Antiinfecciosos/administración & dosificación , Endocarditis Bacteriana/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Abuso de Sustancias por Vía Intravenosa/complicaciones , Administración Oral , Adulto , Antibacterianos/administración & dosificación , Antibióticos Antituberculosos/administración & dosificación , Ciprofloxacina/administración & dosificación , Endocarditis Bacteriana/etiología , Endocarditis Bacteriana/mortalidad , Femenino , Gentamicinas/administración & dosificación , Humanos , Infusiones Intravenosas , Tiempo de Internación , Masculino , Oxacilina/administración & dosificación , Penicilinas/administración & dosificación , Estudios Prospectivos , Rifampin/administración & dosificación , Infecciones Estafilocócicas/etiología , Infecciones Estafilocócicas/mortalidad , Resultado del Tratamiento , Vancomicina/administración & dosificaciónRESUMEN
We conducted a single-center, double-blind, placebo-controlled phase I study in HIV-positive subjects to ascertain the safety, tolerance, bioavailability, pharmacokinetics, and maximum tolerated dose of HPMPC (cidofovir). Five subjects were randomized to receive drug and two to receive placebo at each of three dosage tier (1, 3, and 10 mg/kg) with a 2-week washout period doses. Subjects at 1 and 3 mg/kg received single doses of HPMPC by subcutaneous (s.c.) intravenous (i.v.), and oral (p.o.) routes, while subjects at 10 mg/kg received only i.v. and p.o. doses. For subjects already taking zidovudine, zidovudine AUC values are determined before and then with HPMPC administration for each route. The AUC values of HPMPC were dose-proportional. Subcutaneous bioavailability was essentially equivalent to that of the intravenous route, but the development of transient local fibrosis ad the volumes needed for subcutaneous dosing precluded higher subcutaneous dosing than 3 mg/kg. Oral bioavailability was poor, estimated to be less than 5%. Drug elimination was predominantly renal. Nephrotoxicity in one subject was the only serious adverse event observed. This subject had a significant lag period prior to oral absorption and also had the highest AUC values for both HPMPC and zidovudine. We found no consistent effect on zidovudine AUC concomitant HPMPC.
Asunto(s)
Antivirales/farmacocinética , Citosina/análogos & derivados , Infecciones por VIH/tratamiento farmacológico , Organofosfonatos , Compuestos Organofosforados/farmacocinética , Adolescente , Adulto , Antivirales/efectos adversos , Disponibilidad Biológica , Cidofovir , Citosina/efectos adversos , Citosina/farmacocinética , Método Doble Ciego , Vías de Administración de Medicamentos , Femenino , Infecciones por VIH/metabolismo , Infecciones por VIH/orina , Humanos , Masculino , Persona de Mediana Edad , Compuestos Organofosforados/efectos adversos , Zidovudina/farmacocinéticaRESUMEN
The magnitude and duration of the antiviral and clinical effect of alpha-interferon was measured in healthy volunteers. A single 3 million unit intramuscular dose of interferon was given either alone (controls) or after 72 h of concomitant medications. These medications included either aspirin (650 mg every 4 h), acetaminophen (650 mg every 4 h), or prednisone (40 mg per day). Peripheral blood mononuclear cells were assayed for resistance to vesicular stomatitis virus infection and induction of 2'-5'-oligoadenylate synthetase activity as evidence of interferon's antiviral effect. Co-administration of acetaminophen increased both antiviral parameters by more than 70% (P < 0.05) and reduced symptoms after interferon dosing, compared to controls. Aspirin and prednisone did not demonstrate any significant differences from controls in antiviral effect. As a group, acetaminophen, aspirin, and prednisone reduced the clinical symptoms by 47% compared to controls (P = 0.03) after interferon dosing, although individual drug comparisons failed to reach statistical significance. Independent of treatment group, the changes in antiviral markers after interferon dosing correlated closely with each other (r = 0.72, P < 0.001), but neither correlated with symptoms or fever (r < 0.30, P > 0.05). Acetaminophen enhances the antiviral effects of a single intramuscular dose of alpha-interferon, considering the parameters measured in these healthy volunteers.
Asunto(s)
Acetaminofén/farmacología , Antivirales/farmacología , Aspirina/farmacología , Interferón-alfa/farmacología , Prednisona/farmacología , Infecciones por Rhabdoviridae/tratamiento farmacológico , Virus de la Estomatitis Vesicular Indiana/efectos de los fármacos , 2',5'-Oligoadenilato Sintetasa/biosíntesis , Adulto , Sinergismo Farmacológico , Humanos , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/enzimología , Factores de TiempoRESUMEN
For systemic use, the anti-cytomegalovirus (CMV) agent foscarnet must be given intravenously because oral administration results in unmeasurable or barely measurable plasma levels. At low pH, foscarnet decomposes via an acid-catalyzed decarboxylation; therefore, poor oral bioavailability might be due to decomposition of foscarnet in gastric acid. We evaluated whether increasing gastric pH with ranitidine would enhance the absorption of oral foscarnet in six asymptomatic HIV-infected individuals. Each volunteer received two oral 4000-mg (60 mg/kg) doses of foscarnet, preceded intravenously by a 20-min infusion of either ranitidine 50 mg in D5W or D5W alone in a randomized, double-blind, cross-over study. Intragastric pH monitoring revealed that subjects had evidence of gastric acid production (pH < 2.0) prior to administration of ranitidine and increased gastric pH (pH > 6.0) following ranitidine administration. Most foscarnet plasma levels were below the assay limit of detection (33 microM) with only 4/30 levels detectable after D5W and 8/30 after ranitidine. Urinary recovery of foscarnet increased after ranitidine pretreatment. A mean recovery of 9.9% of the drug was realized in the urine in 24 h following ranitidine pretreatment compared to 6.2% of the dose after D5W pretreatment (P < 0.03). We estimate that 9.9% recovery in the urine in 24 h is equivalent to absorption of 17.1% of the oral dose. In spite of the enhanced bioavailability associated with ranitidine pretreatment, the degree of absorption is still insufficient to achieve effective plasma concentrations for the treatment of CMV or acyclovir-resistant herpes viruses. We conclude that gastric acidity is a determinant of foscarnet absorption, albeit not a major one. Oral foscarnet is unlikely to be clinically useful even if administered in the setting of increased gastric pH.
Asunto(s)
Antivirales/administración & dosificación , Foscarnet/administración & dosificación , Ácido Gástrico/química , Infecciones por VIH/metabolismo , Administración Oral , Antivirales/sangre , Antivirales/farmacocinética , Antivirales/orina , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Estudios Cruzados , Método Doble Ciego , Foscarnet/sangre , Foscarnet/farmacocinética , Foscarnet/orina , Seropositividad para VIH , Antagonistas de los Receptores H2 de la Histamina/farmacología , Humanos , Concentración de Iones de Hidrógeno , Ranitidina/farmacologíaRESUMEN
To assess variation in reported use of preoperative medical tests in patients undergoing cataract surgery and to identify factors that influence test use by different physician groups we performed a national survey of ophthalmologists, anesthesiologists, and internists. Participants included randomly selected members of American professional societies who provided care to one or more patients undergoing cataract surgery in 1991. Responses were obtained from 538 (82%) of 655 eligible ophthalmologists, 109 (76%) of 143 anesthesiologists, and 54 (44%) of 122 internists. Fifty percent of ophthalmologists, 40% of internists, and 33% of anesthesiologists frequently or always obtained a chest x-ray film, while 20% of ophthalmologists, 27% of internists, and 37% of anesthesiologists never obtained a chest x-ray film for patients being considered for cataract surgery who had no history of major medical problems (P < .01 for differences between ophthalmologists and the other groups). Similarly, 70% to 90% of ophthalmologists, 73% to 79% of internists, and 41% to 79% of anesthesiologists frequently or always obtained a complete blood cell count, electrolyte panel, and electrocardiogram, while 4% to 11% of ophthalmologists, 13% to 17% of internists, and 9% to 28% of anesthesiologists never obtained these tests for such patients. Many respondents (32% to 80%) believed tests were unnecessary but cited multiple reasons for obtaining tests (eg, medicolegal concerns and institutional requirements). Many physicians in each group viewed preoperative evaluations as screening opportunities or believed that one of the other two types of physicians "required" tests. We conclude that marked variation exists within and across physician specialties in the use and rationale for use of medical tests in patients undergoing cataract surgery.
Asunto(s)
Anestesiología , Extracción de Catarata , Pruebas Diagnósticas de Rutina/estadística & datos numéricos , Medicina Interna , Oftalmología , Pautas de la Práctica en Medicina/estadística & datos numéricos , Cuidados Preoperatorios/normas , Anestesiología/normas , Actitud del Personal de Salud , Catarata/etiología , Pruebas Diagnósticas de Rutina/normas , Femenino , Humanos , Medicina Interna/normas , Masculino , Anamnesis , Persona de Mediana Edad , Oftalmología/normas , Pautas de la Práctica en Medicina/normas , Encuestas y Cuestionarios , Estados UnidosRESUMEN
Desciclovir (DCV), a prodrug of the antiherpetic agent acyclovir (ACV), is converted in humans to ACV, presumably by xanthine oxidase. Further metabolism of these two compounds was investigated in six human volunteers given 250 mg DCV orally every eight hours for ten days plus one dose on day 11. The mean percent dose recovered in urine (24 hr) on days 2, 5, and 10 as carboxy-DCV (2%) and as carboxy-ACV (14%) along with recoveries of DCV (6%) and ACV (62%) gave a mean total of 84% cleared over a 24-hour period at steady state. Carboxyl metabolites were not found in the plasma of these same subjects at peak DCV concentration on dose day 11. The ratios of DCV and ACV to their corresponding carboxyl metabolites in urine were 4:1 and 3:1, respectively, suggesting that there is little or no difference in the efficiency of these two substrates for oxidation to their carboxylic acid metabolites.
Asunto(s)
Aciclovir/análogos & derivados , Aciclovir/farmacocinética , Preparaciones Farmacéuticas , Profármacos , Aciclovir/sangre , Administración Oral , Adulto , Biotransformación , Cromatografía Líquida de Alta Presión , Humanos , Masculino , Persona de Mediana EdadRESUMEN
We report a case of spontaneous renal hemorrhage that arteriographically appeared to be polyarteritis nodosa but which in fact turned out to be a malignant process. This case stresses the overlapping arteriography of two disease processes and emphasizes the need for tissue diagnosis since radiographic findings may not be as specific as has been reported.
Asunto(s)
Neoplasias Renales/diagnóstico por imagen , Poliarteritis Nudosa/diagnóstico por imagen , Tumor de Wilms/diagnóstico por imagen , Adulto , Angiografía , Diagnóstico Diferencial , Femenino , HumanosRESUMEN
The statistical and practical implications of including second eye surgeries were examined in a clinical trial designed to evaluate the impact of routine preoperative testing prior to cataract surgery on major medical events occurring within seven days following surgery. In order to detect a 0.8% difference in the rates of rare major medical events between the tested and untested groups, 20,000 surgeries must be randomized. About 30% of cataract operations were estimated to be done on second eyes of patients already included in the cohort. Different options for dealing with second eye surgeries were: (1) exclusion of all second eye surgeries, (2) inclusion of second eye surgeries only if the first eye is not enrolled, (3) inclusion of first and second eyes but randomization of patients rather than eyes, and (4) inclusion of first and second eyes but randomization of surgeries rather than patients. The final decision was to exclude second eye surgeries done within 28 days of first eye surgeries, but to rerandomize all other second eye surgeries. Differences in event rates between treatment groups can be estimated using Generalized Estimating Equations, and the association between outcomes of first and second eye operations estimated with pairwise odds ratios. An anticipated small positive correlation is likely to have minimal impact on statistical power and effective sample size.
Asunto(s)
Extracción de Catarata , Catarata/diagnóstico , Cuidados Preoperatorios , Catarata/terapia , Toma de Decisiones , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Cuidados Preoperatorios/métodos , Cuidados Preoperatorios/estadística & datos numéricos , Estudios Retrospectivos , Tamaño de la Muestra , Resultado del TratamientoRESUMEN
The centuries-old antimalarial drug, quinine, continues to play a critical role in the treatment of severe falciparum malaria and uncomplicated malaria in pregnant women. It shares cytochrome P450 (CYP )-mediated metabolic pathways with several commonly used antiretroviral drugs, raising the potential for clinically important drugdrug interactions. A phase I pharmacokinetic study was conducted to assess the impact of long-term use of ritonavir-boosted lopinavir (LPV/r) on quinine pharmacokinetics in healthy volunteers. LP V/r significantly decreased the exposure of quinine and its major active metabolite, 3-hydroxyquinine, in both total and free (unbound) forms. These findings highlight the complex nature of the influence exerted by LPV/r on several of the drug-metabolizing enzymes involved in quinine disposition,including CYP 3A4, UDP-glucuronosyltransferase (UG T), and P-glycoprotein (P-gp). A decline in quinine exposure may compromise clinical efficacy. Further studies are warranted to assess changes in quinine pharmacokinetics and treatment outcomes in patients with acute malaria receiving antiretroviral therapy that includes LPV/r.
Asunto(s)
Fármacos Anti-VIH/farmacología , Antimaláricos/farmacocinética , Lopinavir/farmacología , Quinina/farmacocinética , Ritonavir/farmacología , Adolescente , Adulto , Área Bajo la Curva , Citocromo P-450 CYP3A , Inhibidores del Citocromo P-450 CYP3A , Interacciones Farmacológicas , Electrocardiografía/efectos de los fármacos , Humanos , Lopinavir/farmacocinética , Persona de Mediana Edad , Ritonavir/farmacocinética , Adulto JovenRESUMEN
The authors assessed the ability of the neurophilin compound, timcodar dimesylate, to accelerate the return of epidermal nerve fiber density (ENFD) after a standardized nerve injury in a randomized double blind, placebo controlled trial. While there was no difference in the regeneration rate between the treatment and placebo arms, the baseline ENFD (p = 0.006), height (p = 0.02), and race (p = 0.03) were associated with the regeneration rate.
Asunto(s)
Epidermis/inervación , Regeneración Nerviosa/efectos de los fármacos , Traumatismos de los Nervios Periféricos , Piridinas/uso terapéutico , Adulto , Biopsia , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fibras Nerviosas/patología , Umbral del Dolor , Nervios Periféricos/patología , Nervios Periféricos/fisiopatología , Umbral Sensorial , Muslo , Tacto , Heridas y Lesiones/tratamiento farmacológico , Heridas y Lesiones/patología , Heridas y Lesiones/fisiopatologíaRESUMEN
The syndrome of inappropriate secretion of antidiuretic hormone has been associated with many pulmonary diseases, including tuberculosis and bacterial and viral pneumonia: however, it has not been reported with anaerobic infections or empyema in the absence of pneumonia. We report a patient with empyema due to Bacteroides melaninogenicus, Bacteroides oralis, and Peptostreptococcus who developed the syndrome. Eight hours before the start of therapy, his serum sodium concentration was 127 mEq per liter; serum osmolality, 255 mOsm per kg; urine osmolality, 522 mOsm per kg; urinary sodium concentration, 39 mEq per liter. The creatinine clearance and the adrenocorticotropic hormone stimulation test were normal, and there was no evidence of dehydration. No other causes of the syndrome of inappropriate secretion of antidiuretic hormone were apparent. With drainage and antimicrobial drug therapy, the empyema cleared, and the syndrome resolved in 8 days. The patient has been well, without evidence of inappropriate secretion of antidiuretic hormone, for 9 months. Anaerobic infections and/or empyema without pneumonia can be associated with the syndrome of inappropriate secretion of antidiuretic hormone.
Asunto(s)
Empiema/complicaciones , Vasopresinas/metabolismo , Adulto , Anaerobiosis , Infecciones Bacterianas/complicaciones , Infecciones por Bacteroides/complicaciones , Empiema/microbiología , Humanos , Hiponatremia/etiología , Masculino , Concentración Osmolar , Peptostreptococcus , Prevotella melaninogenica , SíndromeRESUMEN
A bacteriology technologist was found to have acute polyarticular arthritis after a brief prodromal illness. Gram's stain of fluid from the right knee showed pleomorphic gram-negative organisms, while that of fluid from the right elbow and left wrist showed gram-negative cocci and diplococci. Culture of fluid from the right knee yielded Salmonella enteritidis. Cultures of fluid from all other joints, collected after starting therapy, were negative. An enzyme-linked immunosorbent assay of fluid from the right elbow confirmed Neisseria meningitidis, group C. This organism was also isolated from the patient's throat. This case represents concurrent infection of separate joints by two bacterial pathogens, one confirmed by culture and one by current immunodiagnostic techniques.
Asunto(s)
Artritis Infecciosa/etiología , Infecciones Meningocócicas , Infecciones por Salmonella , Adulto , Anticuerpos Antibacterianos/análisis , Articulación del Codo/microbiología , Femenino , Humanos , Articulación de la Rodilla/microbiología , Neisseria meningitidis/aislamiento & purificación , Salmonella enteritidis/inmunología , Líquido Sinovial/microbiología , Articulación de la Muñeca/microbiologíaRESUMEN
The traditional view that Propionibacterium acnes is nonpathogenic for man, except as an agent associated with acne vulgaris, has been refuted. Propionibacterium acnes has been shown to cause endocarditis, meningitis, and other serious infections. We report a case of P acnes infection causing septic arthritis and contributing to a concurrent soft-tissue infection. This case supports and extends previous observations of the clinical importance of P acnes as a pathogen. A positive culture for P acnes cannot be uncritically dismissed as a bothersome contaminant without considering the clinical circumstances.
Asunto(s)
Artritis Infecciosa/etiología , Infecciones Bacterianas , Absceso/etiología , Anciano , Sangre/microbiología , Humanos , Masculino , Propionibacterium acnes/aislamiento & purificación , Líquido Sinovial/microbiologíaRESUMEN
A new oral sustained release formulation of ritodrine was tested for patient tolerance in this open study. The doses tested were 120 mg/day, 240 mg/day, and 360 mg/day. No objective toxicity was seen at any level. Doses of 120 mg/day and 240 mg/day were well-tolerated. Of the subjects who received the 360 mg/day dose, most tolerated it well.
Asunto(s)
Ritodrina/farmacocinética , Administración Oral , Adolescente , Adulto , Preparaciones de Acción Retardada , Femenino , Frecuencia Cardíaca Fetal/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Humanos , Trabajo de Parto Prematuro/prevención & control , Embarazo , Ritodrina/administración & dosificación , Ritodrina/efectos adversosRESUMEN
We studied promotions at Johns Hopkins University School of Medicine to determine whether clinician-teachers are less likely to be promoted or are promoted later in life than researchers and whether those who are promoted have more articles published than those who are not promoted. Over a five-year period, 93 percent of candidates for the rank of associate professor and 79 percent of the candidates for the rank of professor were promoted. There were no significant differences between clinical and research faculty members in terms of the probability that they would be promoted or their age at promotion to either associate professor or professor. Despite these findings, the responses to a questionnaire indicated that former faculty members perceived clinician-teachers as less likely than researchers to be promoted. Those who were promoted had had about twice as many articles published in peer-reviewed journals as those who were not promoted. We recommend improved counseling of medical school faculty members and more extensive discussion of the criteria for promotion and the chances of academic success.
Asunto(s)
Movilidad Laboral , Docentes Médicos , Factores de Edad , Actitud , Maryland , EdiciónRESUMEN
This phase I, double-blind, randomized, placebo-controlled study evaluated the safety of single and multiple (daily for 7 days) subcutaneous administrations of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy human volunteers at seven doses, ranging from 3 to 500 microg/kg/day. No serious or life-threatening adverse events occurred. The most frequently recorded adverse effects were mild injection-site pain, diarrhea, and elevation of liver function tests. No change in neurologic function was noted with these dosing regimens. We conclude that r-metHuNT3 is safe and well tolerated in the dosages used in this study.